ALLOANYISERA AND MOLECULAR PROBES MHC PUBLIC

ALLOONYISERA 和分子探针 MHC Public

• 批准号: 2295108
• 负责人: Frances E Ward
• 金额: $ 34.12万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-07-01 至 1996-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2295108
• 关键词: biomedical resource; histocompatibility typing; human genetic material tag; human tissue; major histocompatibility complex; nucleic acid chemical synthesis; nucleic acid probes; polymerase chain reaction; serology /serodiagnosis; southern blotting

This contract is for the acquisition and characterization of allosera directed against "public specificities" and DNA oligonucleotide probes directed against both "public and private specificities" of the human major histocompatibility complex (MHC). The contractor will screen sera from multiparous women and transplant or blood transfusion recipients against cell panels (This panel shall represent the various ethnic populations of the Contractor's locale in appropriate proportions) well characterized for both public and private specificities of the MHC. The contractor will also synthesize oligonucleotide probes that recognize the public specificities. The Contractor shall authenticate the purity and efficacy of these probes for the detection of specific public specificities and use these probes on the above mentioned cell panel to molecularly type the cell panel in relation to the serological definitions. Methods of screening the molecular probes should include polymerase chain reaction (PCR) technology, oligonucleotide probes and Southern hybridization procedures. The sera of interest will be acquired in larger quantities and more completely characterized by absorption/elution studies as well as standard and antiglobulin enhanced cytotoxic techniques. Cluster analysis of cell/serum reactions will be performed to more precisely define the known and newly described public specificities. At least one hundred milliliters of at least 5 new or replacement sera will be deposited each year by the contractor into the NIAID repository. The contractor shall provide the NIAID with at least 1 mg of at least two new or replacement molecular probes for the genotypic typing of public or private MHC determinants per year to be deposited into the NIAID repository.

该合同用于收购和鉴定 allosera 针对“公共特异性”和 DNA 寡核苷酸探针 针对人类专业的“公共和私人特殊性” 组织相容性复合体（MHC）。 承包商将筛选血清 多产妇女和移植或输血接受者 细胞小组（该小组应代表不同种族群体 承包商的地点以适当的比例）很好地描述了 MHC 的公共和私人特性。 承包商还将 合成识别公共特异性的寡核苷酸探针。 承包商应验证这些探针的纯度和功效 用于检测特定的公共特性并将这些探针用于 上述细胞组对细胞组进行分子分型 与血清学定义的关系。 筛选方法 分子探针应包括聚合酶链反应（PCR）技术， 寡核苷酸探针和Southern杂交程序。 血清为 将获得更大量、更全面的利息 以吸收/洗脱研究以及标准和 抗球蛋白增强细胞毒技术。 细胞/血清的聚类分析 将进行反应以更精确地定义已知的和新的 描述了公共特性。 至少一百毫升 每年至少 5 个新的或替换的血清将由 承包商进入 NIAID 存储库。 承包商应提供 NIAID 含有至少 1 毫克至少两种新分子或替代分子 用于公共或私人 MHC 决定因素基因型分型的探针 年存入 NIAID 存储库。